Stockreport

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF First and only NMPA-approved treatment for patients with CIDP in ChinaThird approval for efgartigimod franchise in China demonstrating Zai Lab’s deep expertise developin [Read more]